India's Dr. Reddy's in $350M deal for Teva products in U.S.

Tablets

Hyderabad-based Dr. Reddy's Laboratories ($RDY) will splash out $350 million to buy an unspecified mix of 8 generic drugs from Teva ($TEVA) as the Israeli firm divests the products as part of antitrust provisions for its purchase of the generics unit of Allergan ($AGN).

The deal comes as Dr. Reddy's has faced headwinds in the U.S. on sales and from the U.S. FDA for manufacturing quality issues for Indian plants that export to the market. Net profit for the company's fourth quarter that ended on March 31 dropped 86%.

"The portfolio being acquired is a mix of filed ANDAs (abbreviated new drug application) pending approval and an approved ANDA, and comprised of complex generic products across diverse dosage forms," Dr. Reddy's said in a press release.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Dr. Reddy's said the purchase will be financed with an unspecified mix of cash available and existing credit lines.

The firm added that moving annual sales for the branded versions of the products came in around $3.5 billion for the year ended April 2016.

In May Dr. Reddy's--India's second largest drugmaker--expanded its OTC and U.S. offering when it bought 6 over-the-counter brands in the cough-and-cold, pain, and dermatology categories in the U.S. from New Jersey-based Ducere Pharma.

- here's the release

Related Articles:
Teva, Allergan generics deal on track to close in June: Analyst
Dr. Reddy’s enters U.S. consumer health market through Ducere Pharma deal
Dr. Reddy's recalling injected drug manufactured by Gland Pharma

Read more on

Suggested Articles

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.

Novartis pivots Shanghai R&D from discovery to development. BeiGene nabs FDA nod for BTK inhibitor Brukinsa. FDA clears Shionogi's antibiotic Fetroja.